C Stroh1,2,3, N Michel4, D Luderer4, S Wolff5,6, V Lange7, F Köckerling7, C Knoll8, T Manger4,5. 1. SRH Wald Klinikum Gera, Gera, Germany. christine.stroh@wkg.srh.de. 2. Institute for Quality Assurance in Operative Medicine, Otto-von-Guericke University, Magdeburg, Germany. christine.stroh@wkg.srh.de. 3. Department of General, Visceral and Paediatric Surgery, SRH Wald Klinikum Gera, Strasse des Friedens 122, D-07548, Gera, Germany. christine.stroh@wkg.srh.de. 4. SRH Wald Klinikum Gera, Gera, Germany. 5. Institute for Quality Assurance in Operative Medicine, Otto-von-Guericke University, Magdeburg, Germany. 6. Otto-von-Guericke University Hospital, Magdeburg, Germany. 7. Vivantes Hospital, Berlin-Spandau, Germany. 8. StatConsult GmbH, Magdeburg, Germany.
Abstract
BACKGROUND: Evidence-based data on optimal approach for prophylaxis of deep venous thrombosis (VTE) and pulmonary embolism (PE) in bariatric operations is discussed. Using antithrombotic prophylaxis, weight adjusted the risk of VTE and its complications have to be balanced with the increased bleeding risk. METHODS: Since 2005, the current situation for bariatric surgery has been examined by quality assurance study in Germany. As a prospective multicenter observational study, data on the type, regimen, and time course of VTE prophylaxis were documented. The incidences of clinically diagnosed VTE or PE were derived during the in-hospital course and follow up. RESULTS: Overall, 31,668 primary bariatric procedures were performed between January 2005 and December 2013. Most performed operations were 3999 gastric banding (GB); 13,722 Roux-en-Y-gastric bypass (RYGBP); and 11,840 sleeve gastrectomies (SG). Gender (p = 0.945), surgical procedure (p = 0.666), or administration of thromboembolic prophylaxis (p = 0.272) had no statistical impact on the DVT incidence. By contrast, BMI (p = 0.116) and the duration of thromboembolic prophylaxis (p = 0.127) did impact the frequency of onset of DVT. CONCLUSION: Age, BMI, male gender, and a previous history of VTE are the most important risk factors. The drug of choice for VTE is heparin. LMWH should be given preference over unfractionated heparins due to their improved pharmacological properties, i.e., better bioavailability and longer half-life as well as ease of use. Despite the low incidence of VTE and PE, there is a lack of evidence. Therefore, prospective randomized studies are necessary to determine the optimal VTE prophylaxis for bariatric surgical patients.
BACKGROUND: Evidence-based data on optimal approach for prophylaxis of deep venous thrombosis (VTE) and pulmonary embolism (PE) in bariatric operations is discussed. Using antithrombotic prophylaxis, weight adjusted the risk of VTE and its complications have to be balanced with the increased bleeding risk. METHODS: Since 2005, the current situation for bariatric surgery has been examined by quality assurance study in Germany. As a prospective multicenter observational study, data on the type, regimen, and time course of VTE prophylaxis were documented. The incidences of clinically diagnosed VTE or PE were derived during the in-hospital course and follow up. RESULTS: Overall, 31,668 primary bariatric procedures were performed between January 2005 and December 2013. Most performed operations were 3999 gastric banding (GB); 13,722 Roux-en-Y-gastric bypass (RYGBP); and 11,840 sleeve gastrectomies (SG). Gender (p = 0.945), surgical procedure (p = 0.666), or administration of thromboembolic prophylaxis (p = 0.272) had no statistical impact on the DVT incidence. By contrast, BMI (p = 0.116) and the duration of thromboembolic prophylaxis (p = 0.127) did impact the frequency of onset of DVT. CONCLUSION: Age, BMI, male gender, and a previous history of VTE are the most important risk factors. The drug of choice for VTE is heparin. LMWH should be given preference over unfractionated heparins due to their improved pharmacological properties, i.e., better bioavailability and longer half-life as well as ease of use. Despite the low incidence of VTE and PE, there is a lack of evidence. Therefore, prospective randomized studies are necessary to determine the optimal VTE prophylaxis for bariatric surgical patients.
Authors: Eva Pardina; Roser Ferrer; Joaquín Rivero; Juan A Baena-Fustegueras; Albert Lecube; Jose M Fort; Víctor Vargas; Roberto Catalán; Julia Peinado-Onsurbe Journal: Obesity (Silver Spring) Date: 2011-12-22 Impact factor: 5.002
Authors: Rodrigo Gonzalez; Krista Haines; Lana G Nelson; Scott F Gallagher; Michel M Murr Journal: Surg Obes Relat Dis Date: 2006 Jan-Feb Impact factor: 4.734
Authors: Jonathan F Finks; Wayne J English; Arthur M Carlin; Kevin R Krause; David A Share; Mousumi Banerjee; John D Birkmeyer; Nancy J Birkmeyer Journal: Ann Surg Date: 2012-06 Impact factor: 12.969
Authors: Gautam Sharma; Zubaidah Nor-Hanipah; Ivy N Haskins; Suriya Punchai; Andrew T Strong; Chao Tu; John H Rodriguez; Phillip R Schauer; Matthew Kroh Journal: Obes Surg Date: 2018-07 Impact factor: 4.129
Authors: Carlos José Goslan; Giórgio Alfredo Pedroso Baretta; Hemuara Grasiela Pestana de Souza; Bruna Zanin Orsi; Esdras Camargo A Zanoni; Marco Antonio Gimenez Lopes; Carlos Alberto Engelhorn Journal: J Vasc Bras Date: 2018 Jan-Mar